Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.

MLA

Matthews, G. M., et al. “Preclinical Screening of Histone Deacetylase Inhibitors Combined with ABT-737, RhTRAIL/MD5-1 or 5-Azacytidine Using Syngeneic Vk*MYC Multiple Myeloma.” Cell Death & Disease, vol. 4, no. 9, Sept. 2013, pp. 1–14. EBSCOhost, https://doi.org/10.1038/cddis.2013.306.

APA

Matthews, G. M., Lefebure, M., Doyle, M. A., Shortt, J., Ellul, J., Chesi, M., Banks, K.-M., Vidacs, E., Faulkner, D., Atadja, P., Bergsagel, P. L., & Johnstone, R. W. (2013). Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma. Cell Death & Disease, 4(9), 1–14. https://doi.org/10.1038/cddis.2013.306

Chicago

Matthews, G. M., M. Lefebure, M. A. Doyle, J. Shortt, J. Ellul, M. Chesi, K.-M. Banks, et al. 2013. “Preclinical Screening of Histone Deacetylase Inhibitors Combined with ABT-737, RhTRAIL/MD5-1 or 5-Azacytidine Using Syngeneic Vk*MYC Multiple Myeloma.” Cell Death & Disease 4 (9): 1–14. doi:10.1038/cddis.2013.306.